Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 228 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Zmax Clear all

Conditions: Urethritis
Interventions: Doxycycline, Placebo, Tinidazole, Azithromycin; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years to 45 Years · Male only
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 4
States / cities: Birmingham, Alabama • New Orleans, Louisiana • Baltimore, Maryland + 1 more

Conditions: Sarcoidosis
Interventions: Antibiotic Regimen, Placebo Regimen; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Childhood Mortality
Interventions: Azithromycin, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 1 Month to 60 Months
Enrollment: 190,238 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: San Francisco, California • Baltimore, Maryland

Conditions: Ureaplasma Infections
Interventions: Azithromycin, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 2 Hours to 72 Hours
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 7
States / cities: Birmingham, Alabama • Newark, Delaware • Baltimore, Maryland + 2 more

Conditions: Bacteria Infection, Respiratory Tract Infections
Interventions: Azithromycin; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Day to 3 Days
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Mycobacterium Infections, Nontuberculous
Interventions: ALIS, Azithromycin, Ethambutol, ELC (matching placebo for ALIS); Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 90
States / cities: Birmingham, Alabama • Fresno, California • Los Angeles, California + 71 more

Conditions: Acute Otitis Media
Interventions: amoxicillin/clavulanate postassium (Augmentin ES-600), azithromycin SR; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 3 Months to 48 Months
Enrollment: 902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 23
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Bellflower, California + 18 more

Conditions: Osteomyelitis
Interventions: oral antibiotics, intravenous antibiotics; Drug · Procedure
Lead sponsor: Julio Ramirez; Other
Eligibility: 18 Years to 100 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Gonorrhoea
Interventions: Azithromycin, Gentamicin, Gemifloxacin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 15 Years to 60 Years
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 5
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 2 more

Conditions: Chronic Bronchitis
Interventions: telithromycin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 35 Years and older
Enrollment: 5,660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Asthma, Asthma Attack, Asthma Exacerbations
Interventions: Inhaled corticosteroid (ICS), Azithromycin, Asthma Symptom Monitoring Web-based Application; Drug · Other
Lead sponsor: DARTNet Institute; Government
Eligibility: 13 Years to 75 Years
Enrollment: 3,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 13
States / cities: Aurora, Colorado • Orlando, Florida • Kansas City, Kansas + 9 more

Conditions: Sickle Cell Disease, Acute Chest Syndrome
Interventions: Azithromycin; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 6 Years to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Jackson, Mississippi • Nashville, Tennessee

Conditions: Bronchiolitis Obliterans Syndrome
Interventions: Pulmonary function testing, FAM Therapy; Procedure · Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 6 Years to 18 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection
Interventions: Hypertonic saline, Azithromycin, Ethambutol, Rifampin; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: New York, New York • Portland, Oregon

Conditions: Healthy
Interventions: Azithromycin, Zithromax®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Pneumonia
Interventions: telithromycin, azithromycin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Trachoma
Interventions: community surveillance and re-treatment; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 12 Months to 7 Years
Enrollment: 2,700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lower Respiratory Tract Infection
Interventions: Azithromycin, Placebo, VIDAS B.R.A.H.M.S Procalcitonin Test (PCT); Drug · Other · Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Atlanta, Georgia • Decatur, Georgia • Durham, North Carolina + 1 more

Conditions: Trachoma
Interventions: Azithromycin; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: Not listed
Enrollment: 320,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Maxillary Sinusitis
Interventions: azithromycin SR (Zithromax; compound: CP-62,993), placebo, levofloxacin; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 59
States / cities: Alabaster, Alabama • Birmingham, Alabama • Hueytown, Alabama + 37 more

Conditions: Chronic Lung Disease
Interventions: Azithromycin, placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 6 Months to 6 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cystic Fibrosis
Interventions: azithromycin, placebo, Tobramycin solution for inhalation; Drug
Lead sponsor: Bonnie Ramsey; Other
Eligibility: 6 Months to 18 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 45
States / cities: Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 40 more

Conditions: Covid19
Interventions: Atovaquone/Azithromycin; Drug
Lead sponsor: HonorHealth Research Institute; Other
Eligibility: 18 Years to 95 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Blepharitis
Interventions: ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined), Azasite, Dexamethasone, Vehicle; Drug · Other
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years and older
Enrollment: 917 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 45
States / cities: Chandler, Arizona • Phoenix, Arizona • Glendale, California + 36 more

Search by objective public record fields.

NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)

Trial of Antimycobacterial Therapy in Sarcoidosis

Mortality Reduction After Oral Azithromycin: Mortality Study

Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants

Early Versus Expectant Treatment of Ureaplasma Infection in Very Low Birth Weight Neonates

Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

A Single, High-Dose Azithromycin Extended Release (60 mg/kg) Compared With 10 Days of High-Dose Amoxicillin Clavulanate in Children With Ear Infections at High Risk of Persistent/Recurrent Ear Infections

Patients Response to Early Switch To Oral:Osteomyelitis Study

Efficacy of Combination Therapies for Gonorrhea Treatment

PERSPECTIVE: Telithromycin - Acute Exacerbation of Chronic Bronchitis

Individualizing Treatment for Asthma in Primary Care (Full Study)

A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease

Early Detection and Management of Bronchiolitis Obliterans Syndrome Following Pediatric Hematopoietic Stem Cell Transplantation

Hypertonic Saline for MAC

A Relative Bioavailability Study of 200mg/5 mL Azithromycin Oral Suspension Under Non-Fasting Conditions

Study Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Telithromycin Once Daily for 7 Days, or Azithromycin Once Daily for 5 Days

Study of Three Alternatives for Mass Treatment in Trachoma Villages of Tanzania

Placebo-Controlled Trial of Antibiotic Therapy in Adults With Suspect Lower Respiratory Tract Infection (LRTI) and a Procalcitonin Level

Kebele Elimination of Trachoma for Ocular Health

A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Sinus Infections in Adults

The Anti-inflammatory Effect of Prophylactic Macrolides on Children With Chronic Lung Disease

OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis

Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection

Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis